Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Sonus Pharmaceuticals and OncoGenex Technologies complete business combination

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

OncoGenex Pharmaceuticals

On August 21, 2008, OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc.) (NASDAQ: OGXI) (the "Company") announced that the Company had completed its acquisition of OncoGenex Technologies and that NASDAQ had approved the commencement of trading in the Company's common stock the same day. Prior to completing the acquisition, the Company changed its name to OncoGenex Pharmaceuticals, amended its authorized share capital and effected a one-for-eighteen reverse stock split. OncoGenex Pharmaceuticals was advised in this transaction by a team from Fasken Martineau led by Iain Mant and that included, among others, Lata Casciano, Prentice Durbin and Frank Schober (tax).

Team

    Subscribe

    Receive email updates from our team

    Subscribe